Table 3.
Comparisons between CCS and Controls for CV Risk Factors and Insulin Resistance
| All CCS (n=319) |
Leukemia (n=110) |
CNS (n=82) |
Solid Tumors (n=127) |
Controls (n=208) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Adjustment | mean ± SE | pb | mean ± SE | pb | mean ± SE | pb | mean ± SE | pb | mean ± SE | |
| Systolic Blood Pressure (mmHg) | 110.9 ± 0.8 | 0.59 | 110.8 ± 1.3 | 0.63 | 109.8 ± 1.3 | 0.84 | 110.7 ± 1.4 | 0.53 | 110.5 ± 1.0 | |
| PFMa | 110.6 ± 0.8 | 0.95 | 110.3 ± 1.3 | 0.93 | 109.0 ± 1.2 | 0.41 | 110.4 ± 1.4 | 0.59 | 110.6 ± 0.9 | |
| Diastolic Blood Pressure (mmHg) | 58.3 ± 0.7 | 0.22 | 58.6 ± 0.9 | 0.10 | 57.8 ± 0.9 | 0.35 | 58.0 ± 1.1 | 0.76 | 57.5 ± 0.7 | |
| PFMa | 58.1 ± 0.7 | 0.35 | 58.3 ± 0.9 | 0.18 | 57.6 ± 0.9 | 0.55 | 57.9 ± 1.1 | 0.81 | 57.6 ± 0.7 | |
| Total Cholesterol (mg/dL) | 154.7 ± 2.1 | 0.004 | 149.8 ± 2.8 | 0.03 | 159.3 ± 4.2 | 0.008 | 152.3 ± 3.4 | 0.23 | 148.3 ± 2.5 | |
| PFMa | 153.2 ± 2.0 | 0.04 | 148.2 ± 2.8 | 0.13 | 155.7 ± 3.7 | 0.05 | 151.3 ± 3.1 | 0.28 | 148.7 ± 2.5 | |
| LDL-Cholesterol (mg/dL) | 89.4 ± 1.9 | 0.002 | 86.7 ± 2.6 | 0.01 | 91.6 ± 3.7 | 0.02 | 88.8 ± 3.3 | 0.10 | 83.7 ± 2.2 | |
| PFMa | 88.0 ± 1.7 | 0.03 | 85.0 ± 2.5 | 0.06 | 88.2 ± 3.1 | 0.11 | 87.8 ± 2.9 | 0.12 | 84.1 ± 2.1 | |
| HDL-Cholesterol (mg/dL) | 47.3 ± 0.8 | 0.21 | 46.1 ± 1.0 | 0.33 | 46.6 ± 1.4 | 0.29 | 47.6 ± 1.3 | 0.29 | 48.4 ± 1.0 | |
| PFMa | 47.8 ± 0.7 | 0.58 | 46.9 ± 0.9 | 0.91 | 47.7 ± 1.3 | 0.77 | 48.1 ± 1.1 | 0.35 | 48.3 ± 0.9 | |
| Triglycerides (mg/dL) | 91.8 ± 5.5 | 0.03 | 85.9 ± 5.3 | 0.38 | 109.1 ± 11.1 | 0.004 | 80.5 ± 3.7 | 0.48 | 84.0 ± 5.9 | |
| PFMa | 89.1 ± 5.4 | 0.20 | 82.4 ± 5.4 | 0.99 | 103.4 ± 10.8 | 0.02 | 78.6 ± 3.2 | 0.61 | 84.8 ± 5.8 | |
| Triglycerides to HDL ratio (mg/dl) | 2.2 ± 0.15 | 0.006 | 2.0 ± 0.15 | 0.19 | 2.7 ± 0.33 | 0.007 | 1.9 ± 0.13 | 0.13 | 1.8 ± 0.16 | |
| PFMa | 2.1 ± 0.14 | 0.05 | 1.9 ± 0.15 | 0.78 | 2.5 ± 0.30 | 0.03 | 1.8 ± 0.11 | 0.16 | 1.9 ± 0.15 | |
| Non-HDL Cholesterol (mg/dl) | 107.4 ± 2.2 | 0.001 | 103.8 ± 2.8 | 0.02 | 112.6 ± 4.1 | 0.002 | 104.6 ± 3.4 | 0.10 | 99.9 ± 2.5 | |
| PFMa | 105.4 ± 1.9 | 0.02 | 101.3 ± 2.7 | 0.12 | 108 ± 3.4 | 0.02 | 103.2 ± 2.9 | 0.11 | 100.0 ± 2.3 | |
| Glucose (mg/dL) | 87.4 ± 1.8 | 0.2 | 85.9 ± 1.1 | 0.58 | 85.1 ± 1.2 | 0.09 | 88.1 ± 4.1 | 0.49 | 89.3 ± 2.3 | |
| PFMa | 87.2 ± 1.8 | 0.14 | 85.6 ± 1.0 | 0.34 | 85.0 ± 1.3 | 0.03 | 87.9 ± 3.9 | 0.43 | 89.3 ± 2.2 | |
| Insulin (mU/L) | 10.6 ± 0.6 | 0.7 | 10.9 ± 0.8 | 0.54 | 12.2 ± 1.4 | 0.20 | 9.1 ± 0.7 | 0.49 | 10.3 ± 0.7 | |
| PFMa | 9.9 ± 0.5 | 0.36 | 9.9 ± 0.8 | 0.46 | 10.6 ± 1.1 | 0.78 | 8.6 ± 0.7 | 0.26 | 10.4 ± 0.6 | |
| HOMA-IR | 2.3 ± 0.1 | 0.8 | 2.3 ± 0.2 | 0.58 | 2.6 ± 0.3 | 0.25 | 2.0 ± 0.1 | 0.42 | 2.2 ± 0.2 | |
| PFMa | 2.1 ± 0.1 | 0.25 | 2.1 ± 0.2 | 0.39 | 2.3 ± 0.3 | 0.94 | 1.8 ± 0.1 | 0.20 | 2.3 ± 0.1 | |
| Mlbm (mg/kg/min) | 12.1 ± 0.3 | 0.002 | 11.5 ± 0.5 | 0.002 | 11.6 ± 0.6 | 0.04 | 12.4 ± 0.5 | 0.05 | 13.4 ± 0.4 | |
| PFMa | 12.2 ± 0.3 | 0.006 | 11.6 ± 0.5 | 0.006 | 11.8 ± 0.6 | 0.11 | 12.5 ± 0.5 | 0.06 | 13.3 ± 0.4 | |
All measures adjusted for age-at-study, sex, race and Tanner score
a
Additional adjustment for percent fat mass (PFM)
b
p-value for comparison between CCS (or subgroup) with controls, based on adjusted regression models
Euglycemic hyperinsulinemic clamps not performed on 3 cases (2 CNS, 1 Solid Tumor) and 1 control, due to pre-existing diagnosis of diabetes